Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 4
2009 2
2011 2
2012 4
2013 6
2014 7
2015 10
2016 13
2017 23
2018 35
2019 21
2020 33
2021 61
2022 56
2023 50
2024 25

Text availability

Article attribute

Article type

Publication date

Search Results

294 results

Results by year

Filters applied: . Clear all
Page 1
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.
Merola JF, Armstrong A, Khattri S, Paek SY, Padilla B, Yue C, Photowala H, Kaplan B, Kristensen LE. Merola JF, et al. J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18. J Dermatolog Treat. 2024. PMID: 38632977 Free article. Clinical Trial.
Bimekizumab safety in moderate to severe plaque psoriasis: Rates of hepatic events and changes in liver parameters over 2 years in randomized phase 3/3b trials.
Lebwohl M, Merola JF, Strober B, Armstrong A, Yoshizaki A, Gisondi P, Szilagyi B, Peterson L, de Cuyper D, Cross N, Davies O, Gottlieb AB. Lebwohl M, et al. Among authors: merola jf. J Am Acad Dermatol. 2024 Apr 6:S0190-9622(24)00568-1. doi: 10.1016/j.jaad.2024.03.041. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38588819
TYK2: an emerging therapeutic target in rheumatic disease.
Morand E, Merola JF, Tanaka Y, Gladman D, Fleischmann R. Morand E, et al. Among authors: merola jf. Nat Rev Rheumatol. 2024 Apr;20(4):232-240. doi: 10.1038/s41584-024-01093-w. Epub 2024 Mar 11. Nat Rev Rheumatol. 2024. PMID: 38467779 Review.
Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ, Ogdie A, Tesser J, Shiff NJ, Zhao RS, Chakravarty SD, Kelleman M, Dodge R, McLean RR, Broadwell A, Kavanaugh A, Merola JF. Mease PJ, et al. Among authors: merola jf. ACR Open Rheumatol. 2024 Feb 28. doi: 10.1002/acr2.11657. Online ahead of print. ACR Open Rheumatol. 2024. PMID: 38417434 Free article.
294 results